Anthropic's Claude Opus 4.6 surfaced 500+ high-severity vulnerabilities that survived decades of expert review. Fifteen days later, they shipped Claude Code Security. Here's what reasoning-based ...
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally ...
5 Things to Know is CNBC's Morning Squawk newsletter, a before-the-bell briefing on the most important news, trends and analysis that investors need to start their trading day. Subscribe here to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results